Примери за използване на Main study showed на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The main study showed the benefit of the highest strength of Exforge HCT in lowering the blood pressure.
At the time of the initial review,the CHMP was concerned that the data from the main study showed only a modest increase of around one month in the time patients given Aplidin lived without their disease getting worse, compared with those treated with dexamethasone alone.
The main study showed a greater reduction in blood pressure with Rasitrio than with combinations of two active substances.
The CHMP noted that the main study showed that Istodax had anti-tumour activity in terms of patients' response to treatment.
The main study showed that Prepandrix containing the adjuvant produced an antibody response that met these criteria.
The results of the main study showed that Obizur was effective in treating serious bleeding episodes in adults with the disorder.
The main study showed that the 3.75 microgram dose of the adjuvanted vaccine produced an antibody response that met these criteria.
The CHMP noted that the main study showed that, compared with clopidogrel, Possia reduces the risk of heart attacks and cardiovascular deaths.
Another main study showed that adding Jardiance to usual treatment reduced adverse cardiovascular(heart and blood vessels) effects.
A main study showed that Fotivda increased the time it took for the disease to get worse by almost 3 months when compared with another approved medicine sorafenib.
The main study showed that the vaccine containing 3.75 micrograms of haemagglutinin and the adjuvant produced an antibody response that met these criteria.
The main study showed that Prepandrix containing 3.75 micrograms of haemagglutinin and the adjuvant produced an antibody response that met these criteria.
A main study showed that Dectova works as well as Tamiflu, with comparable time to discharge patients from hospital or resolution of most of the influenza symptoms.
The main study showed that Polivy is effective at treating patients whose disease was not responding to previous treatment or had returned and who could not have a transplant.
Another main study showed that adding empagliflozin(one of the active substances of Synjardy) to usual treatment reduced adverse cardiovascular(heart and blood vessels) effects.
A main study showed that Ivemend was as effective as Emend at preventing nausea and vomiting in patients undergoing chemotherapy and its side effects are considered to be manageable.
The results of the main study showed an improvement in vision in patients treated with Raxone, and this trend towards a beneficial effect was confirmed by additional data from an expanded access program and a case record survey.
The second main study showed that two doses of Cervarix given 5 to 13 months apart were no less effective in girls aged 9 to 14 than a standard three-dose vaccination was in older subjects: all previously unprotected subjects had developed high levels of protective antibodies against virus types 16 and 18 one month after their last dose.
Results from the main study show that Strimvelis is effective at improving survival of ADA-SCID patients.
Data from the main study show that Lartruvo in combination with doxorubicin improves progressionfree and overall survival of patients with advanced soft tissue sarcoma.
The CHMP noted that there was a need for new COPD treatments and that the main studies showed a modest benefit of Daliresp in patients with severe COPD.
Two main studies showed that Bexsero was effective at stimulating an immune response to N. meningitidis group B. The studies measured the production of protective antibodies which are able to kill the bacteria.
The European Medicines Agency noted that data from the main studies showed high response rates with Zydelig in patients with chronic lymphocytic leukaemia and follicular lymphoma.
The main studies showed that Sixmo was more effective than placebo and at least as effective as sublingual buprenorphine at treating opioid dependence.
Two main studies showed that the combination of allopurinol and lesinurad can help lower uric acid levels when allopurinol on its own is not working well enough.
Two main studies showed that lesinurad in combination with allopurinol reduced the blood levels of uric acid in gout patients in whom allopurinol alone was not sufficient.
The main studies showed that Praxbind is effective at neutralising the effects of Pradaxa, and its action is rapid, complete and sustained.
The main studies showed that Nobivac Bb was effective in reducing the symptoms caused by B. bronchiseptica.
The Committee considered that,taken together, the data from the five main studies showed that treatment with Xeljanz resulted in an improvement in the signs and symptoms of rheumatoid arthritis and the physical function of patients.
The results of the main studies showed that Menveo was as effective as the comparator vaccine in stimulating an immune response against all four types of N. meningitidis oligosaccharides in adults and children from the age of two.